1.	In the middle of April, how many bowel cancer patients were referred to your MDT 1 via the 2‐week wait route compared to normal?
	As many or almost as many as usual (91 to 100% of usual) Small reduction in numbers (71 to 90% of usual) Large reduction in numbers (20 to 70% of usual) Very few 2‐week wait referrals (0 to 19% of usual)
2.	In the middle of April, how many patients at your MDT experienced each of the following changes to planned bowel cancer treatment because of the COVID−19 pande mic?	All or almost all patients (91 to 100%) Majority of patients (51 to 90%) Minority of patients (11 to 50%) Almost none or none (0 to 10%)
	i. Treatments delayed because the patient was diagnosed with COVID−19
	ii. Delays in tissue diagnosis and/or staging investigations
	iii. Treatment plans altered to reflect increased risks from COVID−19 during epidemic
	iv. Delays in treatment due to risk of COVID−19 infection to patient
	v. Delays in treatment due to diversion of healthcare resources for COVID−19 care/preparation
	vi. Temporising treatments used e.g. stent, rectal radiotherapy and long wait
	vii. Emergency admissions while patients waited for diagnosis and/or treatment
	viii. Changes in lengths of treatment and/or choices of chemotherapy
	ix. Deaths due to complications of COVID−19
3.	In the middle of April, how were each of the following services (on‐ or off‐site) affected for elective bowel cancer patients at your MDT?
	i. Diagnostic colonoscopy	Stopped entirely (0 to 10% of usual numbers) Substantially reduced (11 to 70% of usual numbers) Continued more or less the same as before the pandemic (71 to 100% of usual numbers)
	ii. Colorectal resection
	iii. Liver resection
	iv. Lung resection
	v. Neo‐adjuvant chemoradiotherapy
	vi. Adjuvant chemotherapy
4.	In the middle of April, did your MDT have access to a COVID−19 ‘cold site’ for elective colorectal surgery?
	No Yes within every hospital in the trust Yes in certain hospitals in the trust
5.	If you answered ‘Yes in certain hospitals in the trust’ or ‘Yes in another trust/private hospital’, please write the name(s) of these specific hospital sites in the box below.
6.	What would you describe as the single most important lesson your MDT has learned about how to make services for bowel cancer patients as safe and effective as possible during the pandemic?

¹ Multidisciplinary team (MDT): group of CRC experts based within a hospital who discuss and plan the treatment of every CRC patient. The team contains surgeons, medical doctors, nurses, radiologists, and pathologists. Patients from smaller hospitals will be discussed in the closest specialist CRC MDT.